AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10558961 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination hepatitis A/hepatitis B vaccine (3 different manufacturing consistency lots)
Number of subjects: 0
Study 10558961 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination hepatitis A/hepatitis B vaccine
Number of subjects: 0
Study 10558961 — intervention group
Group type: COMPARATOR
Intervention: Separate but concurrent injections of hepatitis A and hepatitis B vaccines
Number of subjects: 0
Study 8904559 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose feeding (GF)
Number of subjects: 7
Study 8904559 — intervention group
Group type: COMPARATOR
Intervention: Fructose feeding (FF)
Number of subjects: 7
Study 1990953 — intervention group
Group type: EXPERIMENTAL
Intervention: Live, attenuated influenza virus by nasal drops and by aerosol
Number of subjects: 14
Study 1990953 — intervention group
Group type: COMPARATOR
Intervention: Placebo via the same route
Number of subjects: 14
Study 6338856 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine hydrochloride (during administration)
Number of subjects: 40
Study 6338856 — intervention group
Group type: COMPARATOR
Intervention: No thioridazine (not receiving)
Number of subjects: 40
Study 30905065 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir plus pegylated IFN-α
Number of subjects: 72
Study 30103529 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and folic acid (IFA) supplements
Number of subjects: 0
Study 30103529 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MMN) supplements
Number of subjects: 0
Study 30103529 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-quantity lipid-based nutrient supplements (MQ-LNS)
Number of subjects: 0
Study 30103529 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 25645288 — intervention group
Group type: EXPERIMENTAL
Intervention: FLS simulator
Number of subjects: 370
Study 25645288 — intervention group
Group type: EXPERIMENTAL
Intervention: LapSim simulator
Number of subjects: 370
Study 24643911 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol ER with AST-120 simultaneously (B)
Number of subjects: 34
Study 24643911 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol ER with AST-120 1 hour later (C)
Number of subjects: 34
Study 24643911 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol ER alone (A)
Number of subjects: 34
Study 22582203 — intervention group
Group type: EXPERIMENTAL
Intervention: PCHMS (n=370)
Number of subjects: 742
Study 22582203 — intervention group
Group type: EXPERIMENTAL
Intervention: PCHMS
Number of subjects: 742
Study 22582203 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (n=372)
Number of subjects: 742
Study 19423132 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 7832
Study 19423132 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 7832
Study 17446982 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate drinking
Number of subjects: 952
Study 17446982 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstaining from alcohol
Number of subjects: 952
Study 17446982 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy drinking
Number of subjects: 952
Study 15242865 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN beta 2.2 microg (0.05 ml)
Number of subjects: 209
Study 15242865 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN beta 44 microg (0.5 ml)
Number of subjects: 209
Study 15242865 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.05 ml or 0.5 ml)
Number of subjects: 209
Study 11792479 — intervention group
Group type: EXPERIMENTAL
Intervention: Active neurocysticercosis with basal ganglia lesions
Number of subjects: 120
Study 11792479 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of lesions in putamen and caudate nuclei
Number of subjects: 120
Study 11792479 — intervention group
Group type: COMPARATOR
Intervention: Comparison of lesions between hemispheres
Number of subjects: 120
Study 11792479 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical manifestations of basal ganglia lesions
Number of subjects: 120
Study 10450500 — intervention group
Group type: EXPERIMENTAL
Intervention: FT-IR spectroscopy with chalcogenide optical fiber
Number of subjects: 0
Study 8539153 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing
Number of subjects: 17
Study 8539153 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 17
Study 2712275 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibreoptic bronchoscope
Number of subjects: 40
Study 2712275 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 40
Study 593192 — intervention group
Group type: EXPERIMENTAL
Intervention: gestonoroncapronate (600 mg/week)
Number of subjects: 99
Study 593192 — intervention group
Group type: COMPARATOR
Intervention: Control group (no gestonoroncapronate)
Number of subjects: 99
Study 31150963 — intervention group
Group type: EXPERIMENTAL
Intervention: Revefenacin 88 μg
Number of subjects: 1055
Study 31150963 — intervention group
Group type: EXPERIMENTAL
Intervention: Revefenacin 175 μg
Number of subjects: 1055
Study 31150963 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium (active control)
Number of subjects: 1055
Study 28928195 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby mCIMT (modified constraint‐induced movement therapy)
Number of subjects: 150
Study 28928195 — intervention group
Group type: COMPARATOR
Intervention: Baby BIM (bimanual therapy)
Number of subjects: 150
Study 28928195 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby mCIMT
Number of subjects: 150
Study 28928195 — intervention group
Group type: COMPARATOR
Intervention: Baby BIM
Number of subjects: 150
Study 28928195 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby mCIMT and Baby BIM
Number of subjects: 150
Study 25386630 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminalia chebula mouthwash
Number of subjects: 90
Study 25386630 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine (active control)
Number of subjects: 90
Study 25386630 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (placebo)
Number of subjects: 90
Study 23949553 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 43
Study 21367356 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 386
Study 21367356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386
Study 19211486 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting in women
Number of subjects: 1564
Study 19211486 — intervention group
Group type: COMPARATOR
Intervention: Carotid artery stenting in men
Number of subjects: 1564
Study 17229239 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine‐2 receptor antagonists
Number of subjects: 3442
Study 17229239 — intervention group
Group type: COMPARATOR
Intervention: Antacids
Number of subjects: 3442
Study 17229239 — intervention group
Group type: COMPARATOR
Intervention: Alginate/antacid combination
Number of subjects: 3442
Study 15054681 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical metronidazole (10 percent)
Number of subjects: 20
Study 15054681 — intervention group
Group type: COMPARATOR
Intervention: Placebo carrier
Number of subjects: 20
Study 11689731 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking activity (3 km/d above daily lifestyle walking)
Number of subjects: 24
Study 11689731 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change in activity)
Number of subjects: 24
Study 9244939 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.04% bupivacaine plus adrenalin 1/2,500,000 and fentanyl 2.5 micrograms/ml (Group II)
Number of subjects: 150
Study 9244939 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine plus adrenalin 1/1,600,000 and fentanyl 2 micrograms/ml (Group III)
Number of subjects: 150
Study 9244939 — intervention group
Group type: COMPARATOR
Intervention: No epidural analgesia (Group I)
Number of subjects: 150
Study 9244939 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (I, II, III)
Number of subjects: 150
Study 7706602 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg beta-carotene
Number of subjects: 2
Study 7706602 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg canthaxanthin
Number of subjects: 2
Study 7706602 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg beta-carotene and 25 mg canthaxanthin (combined dose)
Number of subjects: 2
Study 3190503 — intervention group
Group type: EXPERIMENTAL
Intervention: Levorotatory form of 5-hydroxytryptophan
Number of subjects: 30
Study 3190503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1161368 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of systematic preparation, rehearsal, and supportive care conducted prior to each stressful procedure
Number of subjects: 84
Study 1161368 — intervention group
Group type: COMPARATOR
Intervention: Single-session preparation conducted after admission
Number of subjects: 84
Study 1161368 — intervention group
Group type: COMPARATOR
Intervention: Consistent supportive care given by one nurse at the same points as in the first condition, but including no systematic preparation or rehearsal
Number of subjects: 84
Study 30981618 — intervention group
Group type: EXPERIMENTAL
Intervention: Neodymium: yttrium aluminum garnet laser treatment
Number of subjects: 40
Study 30981618 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroids
Number of subjects: 40
Study 29261737 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 drop of povidone-iodine 5% (PI group)
Number of subjects: 120
Study 29261737 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 drops of povidone-iodine 5% (PI plus group)
Number of subjects: 120
Study 25596150 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (6.77 mmol nitrate)
Number of subjects: 13
Study 25596150 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (0.002 mmol nitrate; placebo)
Number of subjects: 13
Study 24179978 — intervention group
Group type: COMPARATOR
Intervention: Internal socket grafting alone (ISGA)
Number of subjects: 78
Study 24179978 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal and external grafting (IEG)
Number of subjects: 78
Study 22097347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE) (three pills, tid)
Number of subjects: 12
Study 22097347 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three pills, tid)
Number of subjects: 12
Study 18701554 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 643
Study 18701554 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 643
Study 18701554 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 643
Study 22429128 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release doxycycline gel (SRD) administered adjunctively to subgingival ultrasonic/sonic instrumentation (USI)
Number of subjects: 202
Study 22429128 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release doxycycline gel (SRD)
Number of subjects: 202
Study 22429128 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SRD)
Number of subjects: 202
Study 15831798 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mo endurance-training program
Number of subjects: 20
Study 15831798 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 15831798 — intervention group
Group type: EXPERIMENTAL
Intervention: LBNP tolerance
Number of subjects: 20
Study 12401412 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately intensive lifestyle management intervention (2-year duration)
Number of subjects: 0
Study 12401412 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligible patients agreeing to participate in the lifestyle management program
Number of subjects: 0
Study 9619220 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced air warming
Number of subjects: 26
Study 9619220 — intervention group
Group type: COMPARATOR
Intervention: Control group (no forced air warming)
Number of subjects: 26
Study 7609568 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 127)
Number of subjects: 254
Study 7609568 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 127)
Number of subjects: 254
Study 2798445 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day aspirin
Number of subjects: 0
Study 2798445 — intervention group
Group type: COMPARATOR
Intervention: 1000 mg/day aspirin
Number of subjects: 0
Study 356370 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical resection of the spinal lesion and insertion of autologous bone grafts (Rad. series)
Number of subjects: 159
Study 356370 — intervention group
Group type: COMPARATOR
Intervention: Débridement of the spinal focus (Deb. series)
Number of subjects: 159
Study 356370 — intervention group
Group type: EXPERIMENTAL
Intervention: Rad. series
Number of subjects: 159
Study 356370 — intervention group
Group type: COMPARATOR
Intervention: Deb. series
Number of subjects: 159
Study 356370 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS involvement
Number of subjects: 159
Study 356370 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraplegic patients
Number of subjects: 159
Study 356370 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraparetic patients
Number of subjects: 159
Study 11442187 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine as adjunctive therapy
Number of subjects: 554
Study 11442187 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine added to nonselective beta-blocker monotherapy
Number of subjects: 554
Study 11442187 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine added to latanoprost monotherapy
Number of subjects: 554
Study 11442187 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine added to combination regimens including latanoprost
Number of subjects: 554
Study 11442187 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality-of-life measures
Number of subjects: 554
Study 11442187 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 554
Study 11442187 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician rating of brimonidine adjunctive therapy
Number of subjects: 554
Study 30797651 — intervention group
Group type: EXPERIMENTAL
Intervention: venlafaxine XR plus supervised exercise
Number of subjects: 15
Study 30797651 — intervention group
Group type: COMPARATOR
Intervention: venlafaxine XR
Number of subjects: 15
Study 29489818 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hydroxybutyrate infusion
Number of subjects: 9
Study 26352079 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble NCPAP
Number of subjects: 18
Study 26352079 — intervention group
Group type: COMPARATOR
Intervention: Ventilator NCPAP
Number of subjects: 18
Study 25190944 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 8% in oxygen
Number of subjects: 60
Study 25190944 — intervention group
Group type: COMPARATOR
Intervention: Propofol 3 mg/kg
Number of subjects: 60
Study 22825933 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored telephone education about prostate cancer testing
Number of subjects: 490
Study 22825933 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 490
Study 20824548 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling intervention (IG, n=28)
Number of subjects: 54
Study 20824548 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n=26)
Number of subjects: 54
Study 17355168 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0
Study 17355168 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0
Study 17355168 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 15310636 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron
Number of subjects: 34
Study 15310636 — intervention group
Group type: COMPARATOR
Intervention: 4 mL saline (placebo)
Number of subjects: 34
Study 12213884 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐I (30 μg/kg·d) for 1 yr
Number of subjects: 0
Study 12213884 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg/L IGF‐I (13 nM)
Number of subjects: 0
Study 9797626 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Continuous Positive Airway Pressure (NCPAP)
Number of subjects: 92
Study 9797626 — intervention group
Group type: COMPARATOR
Intervention: Headbox oxygen
Number of subjects: 92
Study 9797626 — intervention group
Group type: EXPERIMENTAL
Intervention: NCPAP
Number of subjects: 92
Study 9797626 — intervention group
Group type: EXPERIMENTAL
Intervention: NCPAP and Headbox oxygen
Number of subjects: 92
Study 8584179 — intervention group
Group type: EXPERIMENTAL
Intervention: Subvocal rehearsal and inner ear/inner voice partnership in auditory imagery tasks
Number of subjects: 0
Study 8584179 — intervention group
Group type: EXPERIMENTAL
Intervention: Subvocal rehearsal in distinguishing voiced and unvoiced consonants
Number of subjects: 0
Study 8584179 — intervention group
Group type: EXPERIMENTAL
Intervention: Subvocal rehearsal in making homophone judgements
Number of subjects: 0
Study 2706415 — intervention group
Group type: EXPERIMENTAL
Intervention: CPH 82 (semisynthetic lignan glycosides)
Number of subjects: 30
Study 2706415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2706415 — intervention group
Group type: EXPERIMENTAL
Intervention: CPH 82
Number of subjects: 30
Study 70585 — intervention group
Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid (600 mg/day)
Number of subjects: 44
Study 70585 — intervention group
Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid (150 mg/day)
Number of subjects: 44
Study 70585 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 44
Study 31568109 — intervention group
Group type: EXPERIMENTAL
Intervention: Online education only
Number of subjects: 100
Study 31568109 — intervention group
Group type: COMPARATOR
Intervention: Online education plus a 3-hour face-to-face training session
Number of subjects: 100
Study 31568109 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Online education only and Online education plus face-to-face)
Number of subjects: 100
Study 29187391 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit gender bias measured by Implicit Association Test
Number of subjects: 503
Study 25150913 — intervention group
Group type: EXPERIMENTAL
Intervention: True facilitative KinTape
Number of subjects: 30
Study 25150913 — intervention group
Group type: COMPARATOR
Intervention: Sham KinTape
Number of subjects: 30
Study 25150913 — intervention group
Group type: COMPARATOR
Intervention: No KinTape
Number of subjects: 30
Study 23294034 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV 600 mg once daily
Number of subjects: 245
Study 23294034 — intervention group
Group type: EXPERIMENTAL
Intervention: AZV/r 300 mg and ritonavir 100 mg once daily
Number of subjects: 245
Study 23294034 — intervention group
Group type: COMPARATOR
Intervention: LPV/r 400 mg and ritonavir 100 mg twice daily
Number of subjects: 245
Study 21812910 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous infiltration of ketamine 1 mg/kg (Group KS1)
Number of subjects: 120
Study 21812910 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous infiltration of ketamine 2 mg/kg (Group KS2)
Number of subjects: 120
Study 21812910 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine 1 mg/kg (Group KI)
Number of subjects: 120
Study 21812910 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous infiltration of normal saline 20 mL (Group C)
Number of subjects: 120
Study 18194386 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukoreduced red blood cell (RBC) transfusions
Number of subjects: 0
Study 18194386 — intervention group
Group type: COMPARATOR
Intervention: Buffy coat-depleted red blood cell (RBC) transfusions
Number of subjects: 0
Study 18194386 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh-frozen plasma (FFP) transfusions
Number of subjects: 0
Study 18194386 — intervention group
Group type: EXPERIMENTAL
Intervention: MBL deficiency (MBL ≤ 80 ng/mL)
Number of subjects: 0
Study 16472564 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 - Initial injection on 1st-5th day of menstrual cycle, subsequent injections every 30 +/- 3 days.
Number of subjects: 365
Study 16472564 — intervention group
Group type: COMPARATOR
Intervention: Group 2 - Initial injection between Days 7 and 10 of menstrual cycle, subsequent injections 7-10 days after Day 1 of withdrawal bleeding.
Number of subjects: 365
Study 12702997 — intervention group
Group type: EXPERIMENTAL
Intervention: Low helical pitch acquisition (3:1)
Number of subjects: 384
Study 12702997 — intervention group
Group type: COMPARATOR
Intervention: High helical pitch acquisition (6:1)
Number of subjects: 384
Study 10473015 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent testing (twice per week) for 10 weeks
Number of subjects: 166
Study 10473015 — intervention group
Group type: COMPARATOR
Intervention: Less frequent testing (approximately weekly or every 3-4 weeks)
Number of subjects: 166
Study 8738729 — intervention group
Group type: COMPARATOR
Intervention: Propranolol alone (n = 19)
Number of subjects: 34
Study 8738729 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol plus molsidomine (n = 15)
Number of subjects: 34
Study 1742750 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 18
Study 1742750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7020778 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent EMG biofeedback from the forehead area
Number of subjects: 24
Study 7020778 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent EMG feedback from a tape recorder (single blind)
Number of subjects: 24
Study 7020778 — intervention group
Group type: COMPARATOR
Intervention: Auditory feedback (yoked control)
Number of subjects: 24
Study 31133406 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion stimulation
Number of subjects: 1078
Study 31133406 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 1078
Study 27125223 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive low glucose suspend (PLGS) system
Number of subjects: 127
Study 25240630 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocriplasmin 125 μg
Number of subjects: 652
Study 25240630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652